RIGEL PHARMACEUTICALS INC (RIGL) Fundamental Analysis & Valuation
NASDAQ:RIGL • US7665597024
Current stock price
30.72 USD
+0.25 (+0.82%)
At close:
30.72 USD
0 (0%)
After Hours:
This RIGL fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. RIGL Profitability Analysis
1.1 Basic Checks
- In the past year RIGL was profitable.
- RIGL had a positive operating cash flow in the past year.
- The reported net income has been mixed in the past 5 years: RIGL reported negative net income in multiple years.
- The reported operating cash flow has been mixed in the past 5 years: RIGL reported negative operating cash flow in multiple years.
1.2 Ratios
- RIGL has a better Return On Assets (71.46%) than 99.42% of its industry peers.
- The Return On Equity of RIGL (93.75%) is better than 99.42% of its industry peers.
- The Return On Invested Capital of RIGL (23.92%) is better than 97.87% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 71.46% | ||
| ROE | 93.75% | ||
| ROIC | 23.92% |
ROA(3y)20.24%
ROA(5y)1.28%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin of RIGL (124.72%) is better than 98.64% of its industry peers.
- With an excellent Operating Margin value of 42.63%, RIGL belongs to the best of the industry, outperforming 98.26% of the companies in the same industry.
- RIGL's Gross Margin of 93.33% is amongst the best of the industry. RIGL outperforms 93.99% of its industry peers.
- RIGL's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 42.63% | ||
| PM (TTM) | 124.72% | ||
| GM | 93.33% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.81%
GM growth 5Y-1.21%
2. RIGL Health Analysis
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), RIGL is creating value.
- The number of shares outstanding for RIGL has been increased compared to 1 year ago.
- Compared to 5 years ago, RIGL has less shares outstanding
- The debt/assets ratio for RIGL has been reduced compared to a year ago.
2.2 Solvency
- Based on the Altman-Z score of 1.71, we must say that RIGL is in the distress zone and has some risk of bankruptcy.
- RIGL has a better Altman-Z score (1.71) than 63.18% of its industry peers.
- RIGL has a debt to FCF ratio of 0.69. This is a very positive value and a sign of high solvency as it would only need 0.69 years to pay back of all of its debts.
- The Debt to FCF ratio of RIGL (0.69) is better than 95.16% of its industry peers.
- A Debt/Equity ratio of 0.06 indicates that RIGL is not too dependend on debt financing.
- RIGL has a Debt to Equity ratio (0.06) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.06 | ||
| Debt/FCF | 0.69 | ||
| Altman-Z | 1.71 |
ROIC/WACC2.42
WACC9.9%
2.3 Liquidity
- A Current Ratio of 2.42 indicates that RIGL has no problem at all paying its short term obligations.
- With a Current ratio value of 2.42, RIGL is not doing good in the industry: 72.09% of the companies in the same industry are doing better.
- A Quick Ratio of 2.30 indicates that RIGL has no problem at all paying its short term obligations.
- Looking at the Quick ratio, with a value of 2.30, RIGL is doing worse than 71.32% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.42 | ||
| Quick Ratio | 2.3 |
3. RIGL Growth Analysis
3.1 Past
- The Earnings Per Share has grown by an impressive 593.62% over the past year.
- RIGL shows a strong growth in Revenue. In the last year, the Revenue has grown by 64.15%.
- The Revenue has been growing by 22.06% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)593.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.75%
Revenue 1Y (TTM)64.15%
Revenue growth 3Y34.78%
Revenue growth 5Y22.06%
Sales Q2Q%21.19%
3.2 Future
- The Earnings Per Share is expected to decrease by -2.44% on average over the next years.
- The Revenue is expected to grow by 6.25% on average over the next years.
EPS Next Y-35.44%
EPS Next 2Y-24.19%
EPS Next 3Y-16.16%
EPS Next 5Y-2.44%
Revenue Next Year-3.09%
Revenue Next 2Y4.53%
Revenue Next 3Y6.64%
Revenue Next 5Y6.25%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. RIGL Valuation Analysis
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 4.71 indicates a rather cheap valuation of RIGL.
- Based on the Price/Earnings ratio, RIGL is valued cheaply inside the industry as 98.84% of the companies are valued more expensively.
- RIGL is valuated cheaply when we compare the Price/Earnings ratio to 27.47, which is the current average of the S&P500 Index.
- RIGL is valuated cheaply with a Price/Forward Earnings ratio of 7.30.
- Based on the Price/Forward Earnings ratio, RIGL is valued cheaper than 98.45% of the companies in the same industry.
- When comparing the Price/Forward Earnings ratio of RIGL to the average of the S&P500 Index (22.62), we can say RIGL is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 4.71 | ||
| Fwd PE | 7.3 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, RIGL is valued cheaper than 98.84% of the companies in the same industry.
- Based on the Price/Free Cash Flow ratio, RIGL is valued cheaply inside the industry as 98.45% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 7.5 | ||
| EV/EBITDA | 2.74 |
4.3 Compensation for Growth
- RIGL has a very decent profitability rating, which may justify a higher PE ratio.
- RIGL's earnings are expected to decrease with -16.16% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-24.19%
EPS Next 3Y-16.16%
5. RIGL Dividend Analysis
5.1 Amount
- No dividends for RIGL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
RIGL Fundamentals: All Metrics, Ratios and Statistics
30.72
+0.25 (+0.82%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-03 2026-03-03/amc
Earnings (Next)05-04 2026-05-04
Inst Owners90.16%
Inst Owner Change0.01%
Ins Owners2.98%
Ins Owner Change6.76%
Market Cap567.71M
Revenue(TTM)294.28M
Net Income(TTM)367.02M
Analysts80
Price Target52.22 (69.99%)
Short Float %21.28%
Short Ratio10.89
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)28.95%
Min EPS beat(2)-9.57%
Max EPS beat(2)67.46%
EPS beat(4)3
Avg EPS beat(4)168.74%
Min EPS beat(4)-9.57%
Max EPS beat(4)592.43%
EPS beat(8)6
Avg EPS beat(8)228.66%
EPS beat(12)10
Avg EPS beat(12)171.43%
EPS beat(16)13
Avg EPS beat(16)137.97%
Revenue beat(2)1
Avg Revenue beat(2)4.83%
Min Revenue beat(2)-0.39%
Max Revenue beat(2)10.05%
Revenue beat(4)3
Avg Revenue beat(4)10.23%
Min Revenue beat(4)-0.39%
Max Revenue beat(4)19.17%
Revenue beat(8)6
Avg Revenue beat(8)10%
Revenue beat(12)10
Avg Revenue beat(12)7.75%
Revenue beat(16)12
Avg Revenue beat(16)11.69%
PT rev (1m)8.94%
PT rev (3m)9.71%
EPS NQ rev (1m)0%
EPS NQ rev (3m)9.35%
EPS NY rev (1m)1.64%
EPS NY rev (3m)-4.29%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)7.25%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.56%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 4.71 | ||
| Fwd PE | 7.3 | ||
| P/S | 1.93 | ||
| P/FCF | 7.5 | ||
| P/OCF | 7.5 | ||
| P/B | 1.45 | ||
| P/tB | 1.55 | ||
| EV/EBITDA | 2.74 |
EPS(TTM)6.52
EY21.22%
EPS(NY)4.21
Fwd EY13.7%
FCF(TTM)4.09
FCFY13.33%
OCF(TTM)4.09
OCFY13.33%
SpS15.92
BVpS21.18
TBVpS19.84
PEG (NY)N/A
PEG (5Y)N/A
Graham Number55.7467 (81.47%)
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 71.46% | ||
| ROE | 93.75% | ||
| ROCE | 30.28% | ||
| ROIC | 23.92% | ||
| ROICexc | 38.21% | ||
| ROICexgc | 42.24% | ||
| OM | 42.63% | ||
| PM (TTM) | 124.72% | ||
| GM | 93.33% | ||
| FCFM | 25.71% |
ROA(3y)20.24%
ROA(5y)1.28%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.81%
GM growth 5Y-1.21%
F-Score6
Asset Turnover0.57
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.06 | ||
| Debt/FCF | 0.69 | ||
| Debt/EBITDA | 0.18 | ||
| Cap/Depr | 0% | ||
| Cap/Sales | 0% | ||
| Interest Coverage | 19.09 | ||
| Cash Conversion | 59.16% | ||
| Profit Quality | 20.61% | ||
| Current Ratio | 2.42 | ||
| Quick Ratio | 2.3 | ||
| Altman-Z | 1.71 |
F-Score6
WACC9.9%
ROIC/WACC2.42
Cap/Depr(3y)409.8%
Cap/Depr(5y)265.74%
Cap/Sales(3y)4.35%
Cap/Sales(5y)2.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)593.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.75%
EPS Next Y-35.44%
EPS Next 2Y-24.19%
EPS Next 3Y-16.16%
EPS Next 5Y-2.44%
Revenue 1Y (TTM)64.15%
Revenue growth 3Y34.78%
Revenue growth 5Y22.06%
Sales Q2Q%21.19%
Revenue Next Year-3.09%
Revenue Next 2Y4.53%
Revenue Next 3Y6.64%
Revenue Next 5Y6.25%
EBIT growth 1Y418.63%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-17.48%
EBIT Next 3Y9.38%
EBIT Next 5YN/A
FCF growth 1Y143.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y140.4%
OCF growth 3YN/A
OCF growth 5YN/A
RIGEL PHARMACEUTICALS INC / RIGL Fundamental Analysis FAQ
What is the ChartMill fundamental rating of RIGEL PHARMACEUTICALS INC (RIGL) stock?
ChartMill assigns a fundamental rating of 6 / 10 to RIGL.
What is the valuation status for RIGL stock?
ChartMill assigns a valuation rating of 8 / 10 to RIGEL PHARMACEUTICALS INC (RIGL). This can be considered as Undervalued.
What is the profitability of RIGL stock?
RIGEL PHARMACEUTICALS INC (RIGL) has a profitability rating of 6 / 10.
Can you provide the financial health for RIGL stock?
The financial health rating of RIGEL PHARMACEUTICALS INC (RIGL) is 6 / 10.
What is the earnings growth outlook for RIGEL PHARMACEUTICALS INC?
The Earnings per Share (EPS) of RIGEL PHARMACEUTICALS INC (RIGL) is expected to decline by -35.44% in the next year.